Nanoform Finland Plc and CBC Co. Collaborate to Advance Nanomedicine Engineering in Japan

Nanoform Finland Plc has recently entered into a strategic partnership with CBC Co. The collaboration will leverage CBC’s extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform’s nanomedicine engineering technologies. Nanoformed medicines have proven to overcome bioavailability issues, reduce dose size, and pill burden to enhance patient acceptance, for both new drugs and existing product reformulations.

The partnership is seen as a significant milestone in Nanoform’s mission to deliver meaningful innovation to patients more rapidly. Christian Jones, Chief Commercial Officer at Nanoform, expressed his excitement about the partnership and emphasized the importance of bringing innovative nanotechnology to improve medicines globally.

Shinya Miyairi, Managing Executive Officer at CBC, believes that Nanoform’s technologies align well with the Japanese market’s need for medicines with higher bioavailability and fewer, smaller doses for success. Nanoform’s technology has demonstrated efficacy in various in vitro and in vivo studies across different routes of administration and molecule types.

The partnership between Nanoform and CBC has already begun, with planned joint activities to showcase their collaboration. This includes Nanoform’s representation by CBC at the CPHI Japan event scheduled to take place at Tokyo Big Sight, Tokyo, from April 17-19, 2024. The partnership is set to bring innovative nanomedicine solutions to the forefront of the pharmaceutical industry in Japan.

Nanomedicine engineering has shown great potential for improving patient outcomes by addressing some of the most significant challenges faced by modern medicine. As such, this partnership between two leading companies in their respective fields represents an exciting opportunity for continued innovation and progress in this area.

In recent years, there has been a growing focus on developing nanotechnologies that can be used to deliver drugs more efficiently and effectively than traditional methods. These advancements have led to the development of new treatments for a wide range of diseases and conditions.

One area where nanotechnology has shown particular promise is in addressing bioavailability issues associated with certain medications. Bioavailability refers to how much of a drug reaches its intended target after it is administered orally or through injection.

For many drugs, achieving adequate bioavailability can be challenging due to factors such as poor absorption or rapid metabolism. In these cases, nanotechnologies can be used to improve drug delivery by encapsulating medications within tiny particles that protect them from degradation or metabolism until they reach their target site.

Another advantage of using nanomedicine engineering technologies is that they can help reduce dose size and pill burden. This can be particularly beneficial for patients who may struggle with taking large numbers of pills or who have difficulty swallowing larger tablets or capsules.

Overall, this partnership between Nanoform Finland Plc and CBC Co represents an exciting opportunity for continued innovation and progress in the field of nanomedicine engineering. By leveraging each other’s strengths and expertise, these companies are poised to develop novel solutions that can address some of the most pressing challenges faced by modern medicine today.